Your browser doesn't support javascript.
A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.
Ejemel, Monir; Li, Qi; Hou, Shurong; Schiller, Zachary A; Tree, Julia A; Wallace, Aaron; Amcheslavsky, Alla; Kurt Yilmaz, Nese; Buttigieg, Karen R; Elmore, Michael J; Godwin, Kerry; Coombes, Naomi; Toomey, Jacqueline R; Schneider, Ryan; Ramchetty, Anudeep S; Close, Brianna J; Chen, Da-Yuan; Conway, Hasahn L; Saeed, Mohsan; Ganesa, Chandrashekar; Carroll, Miles W; Cavacini, Lisa A; Klempner, Mark S; Schiffer, Celia A; Wang, Yang.
  • Ejemel M; MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA.
  • Li Q; MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA.
  • Hou S; Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Boston, MA, USA.
  • Schiller ZA; MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA.
  • Tree JA; National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, UK.
  • Wallace A; MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA.
  • Amcheslavsky A; MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA.
  • Kurt Yilmaz N; Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Boston, MA, USA.
  • Buttigieg KR; National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, UK.
  • Elmore MJ; National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, UK.
  • Godwin K; National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, UK.
  • Coombes N; National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, UK.
  • Toomey JR; MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA.
  • Schneider R; MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA.
  • Ramchetty AS; MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA.
  • Close BJ; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
  • Chen DY; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
  • Conway HL; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
  • Saeed M; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
  • Ganesa C; MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA.
  • Carroll MW; National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, UK.
  • Cavacini LA; MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA. Lisa.Cavacini@umassmed.edu.
  • Klempner MS; MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA. Mark.Klempner@umassmed.edu.
  • Schiffer CA; Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Boston, MA, USA. Celia.Schiffer@umassmed.edu.
  • Wang Y; MassBiologics of the University of Massachusetts Medical School, Boston, MA, USA. Yang.Wang@umassmed.edu.
Nat Commun ; 11(1): 4198, 2020 08 21.
Article in English | MEDLINE | ID: covidwho-724360
ABSTRACT
COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity, or as a therapeutic, has yet been developed to SARS-CoV-2. In this study, we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks ACE2 receptor binding, by overlapping the ACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in 293 cells expressing ACE2. When converted to secretory IgA, MAb326 also neutralizes authentic SARS-CoV-2 virus while the IgG isotype shows no neutralization. Our results suggest that SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin A / Peptidyl-Dipeptidase A / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / Betacoronavirus / Antibodies, Monoclonal Type of study: Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2020 Document Type: Article Affiliation country: S41467-020-18058-8

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin A / Peptidyl-Dipeptidase A / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / Betacoronavirus / Antibodies, Monoclonal Type of study: Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2020 Document Type: Article Affiliation country: S41467-020-18058-8